Azathioprine: current status and future considerations.
El-Azhary
Rokea A
RA
Department of Dermatology, Mayo Clinic, Rochester, Minnesota 55905, USA. elazhary.rokea2@mayo.edu
D000964:Antimetabolites, Antineoplastic / Q000097:blood; D001379:Azathioprine / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D003879:Dermatologic Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D004347:Drug Interactions; D004912:Erythrocytes / Q000378:metabolism; D006801:Humans; D008780:Methyltransferases / Q000187:drug effects / Q000235:genetics* / Q000378:metabolism; D015394:Molecular Structure; D011110:Polymorphism, Genetic; D013866:Thioguanine / Q000097:blood
D000964:Antimetabolites, Antineoplastic; D003879:Dermatologic Agents; D008780:Methyltransferases; C022745:thiopurine methyltransferase; D013866:Thioguanine; D001379:Azathioprine